Responses
S7a – New therapeutic candidates
S7A:8 Efficacy and safety of ustekinumab, an interleukin 12/23 inhibitor, in patients with active systemic lupus erythematosus: results of a phase 2, randomised placebo-controlled study
Compose a Response to This Article
Other responses
No responses have been published for this article.